BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T052433
CREATED:20200817T090658Z
LAST-MODIFIED:20200817T090658Z
UID:26779-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
DESCRIPTION:Revolutionize the Development & Delivery of Neurological Gene Therapies  \nReturning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer\, Biogen\, Voyager and Novartis\, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges\, enabling you to accelerate the development of your neurological gene therapy candidate. \nDon’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS\, optimize translational modelling approaches and discover targeted\, efficacious\, and safe vectors to revolutionize the treatment of neurological disorders. \nTo learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-for-neurological-disorders-running-digitally-for-2020/
LOCATION:Vitual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T052433
CREATED:20200819T090705Z
LAST-MODIFIED:20200819T090705Z
UID:26807-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field\, such as successful determination and prediction of RNA structure and role in disease\, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development. \n \nWith numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules\, join leading biopharmaceutical directors\, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes. \nThe world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA\, opening the door to RNA targeted small molecule drug discovery. \n  \n  \n\nExplore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute\, Anima Biotech & Arrakis Therapeutics\n\n  \n\nSuccessfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics\, Accent Therapeutics & Saverna Therapeutics\n\n  \n\nExpand your knowledge of RNA structure\, function & role in disease with insights from Yale University\, H3 Biomedicine & Whitehead Institute for Biomedical Research\n\n  \n\nAdvance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University\n\n  \n\nOvercome binding\, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche\, University of California San Diego & Novartis\n\n \nTo know more about 3rd RNA-Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201210
DTSTAMP:20260515T052433
CREATED:20201020T131537Z
LAST-MODIFIED:20201020T131537Z
UID:27562-1607385600-1607558399@www.pharmajournalist.com
SUMMARY:Decentralized Clinical Trails Summit
DESCRIPTION:Strengthen Your Operational and Compliance Protocols to Accelerate Technology-Enabled\, Patient-Centric\, and Cost-Efficient Decentralized Clinical Trials \nWith the potential to improve recruitment rates\, simplify compliance\, reduce drop-out rates\, and speed-up your product’s time to market\, decentralized clinical trials represent an opportunity to rethink and refresh how research studies are conducted\, while keeping the patient at the heart of all trials. \n \nDespite this\, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here\, and keeping pace with the rest of the industry means preparing your internal processes for the change. \nCreated in conjunction with clinical trial leaders from big and small pharma\,  forward thinking  academics\, and research institutes\, the programme for this year’s Decentralized Clinical summit has been designed to help you to develop the toolkit you need to run successful decentralised trials. Join over 100+ peers this December to tackle issues such as: using digital tools and wearables\, maintaining data quality and integrity\, simplifying e-consent\, optimising patient recruitment\, restructuring project teams\, rethinking trial design and undertaking study-model matching. \nTo know more about Decentralized Clinical Trails Summit please click here.
URL:https://www.pharmajournalist.com/event/decentralized-clinical-trails-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T052433
CREATED:20201026T092432Z
LAST-MODIFIED:20201026T092432Z
UID:27669-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:As the tools and technologies that are available to study the skin microbiome become cheaper and more accessible\, the fundamental mechanisms that link the skin microbiome with skin health are becoming stronger. The demand for skin microbiome products is advancing rapidly which is only being reflected in the increasing number of products on the market that claim to modulate the microbiome. \nDespite this growing opportunity\, there are still a number of basic and clinical science that need addressing to ensure that industry researchers are creating products that demonstrate true impact in patients and consumers. \n \nThe 3rd Microbiome Movement ­– Skin Health & Dermatology Summit returns to unite leaders from academia and industry to address the unique challenges that working within the skin microbiome possesses\, with the goal to accelerate microbiome-targeted therapeutics and cosmetics. \nWith discussions focusing on targeting the microbiome to treat inflammatory skin disease\, exploring how pre\, pro and post biotics can be optimized to improve skin health as well as a view into the regulatory and patent landscape; this opportunity is not to be missed. This is not to mention our new Pre-Conference Commercialization & Marketing Focus Day that will provide a deep dive into consumer education and product differentiation. \nTo know more about 3rd Microbiome Movement – Skin Health & Dermatology Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201209
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T052433
CREATED:20191030T073844Z
LAST-MODIFIED:20200923T084604Z
UID:23096-1607472000-1608335999@www.pharmajournalist.com
SUMMARY:Medical Fair Asia 2020 Digital Edition
DESCRIPTION:MEDICAL FAIR ASIA 2020 Digital Edition is set to take place from 9 – 18 December 2020. The shift to a digital event for its 13th edition is in response to the dynamic situation of the COVID-19 pandemic\, where travel and physical restrictions are still in effect globally. \n \nAs the leading medical and healthcare exhibition in the region\, the well-established exhibition will feature the latest medical technology and innovations\, and healthcare equipment and supplies for the Hospital\, Diagnostics\, Pharmaceutical\, Medical & Rehabilitation sectors. \nMoving from in-person interactions at a physical trade event to making virtual connections anywhere in the world\, MEDICAL FAIR ASIA Digital Edition aims to deliver the onsite benefits of a trade fair but with all the convenience of an online experience. \nMEDICAL FAIR ASIA is organised by Messe Düsseldorf Asia\, the subsidiary of Messe Düsseldorf GmbH based in Germany and organiser of the world’s no. 1 medical fair – MEDICA. The exhibition is also a member of the MEDICAlliance\, the global network for medical trade fairs worldwide. \nFor more information about Medical Fair Asia 2020 and to register\, visit https://www.medicalfair-asia.com/
URL:https://www.pharmajournalist.com/event/medical-fair-asia-2020/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Messe Duesseldorf Asia":MAILTO:medicalfair-asia@mda.com.sg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210113
DTEND;VALUE=DATE:20210115
DTSTAMP:20260515T052433
CREATED:20200910T124837Z
LAST-MODIFIED:20201015T100412Z
UID:26969-1610496000-1610668799@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices 2021
DESCRIPTION:Device design\, regulatory and strategic pathways for parenteral drug delivery \nSMi is proud to present the 13th Annual Pre-Filled Syringes Conference on 13th and 14th January 2021. \nThe pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration\, a rise in biologics\, large-volume delivery and the delayed EU MDR at the forefront of the field\, SMi’s 13th annual event will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry. \nTopics of discussion will include the latest updates on the EU MDR and Article 117\, advances in novel drug products and biologics\, parenteral packaging for pre-filled syringes\, innovations in device design and platforms for combination products\, lifecycle management and much more… \n \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nAs Europe’s first Pre-Filled Syringes Conference of 2021\, this event is not to be missed. We look forward to welcoming you to the conference in January. \nBENEFITS OF ATTENDING:  \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nView the full agenda and speaker line-up online: www.pre-filled-syringes.com/pjwl \nPlus\, pre-conference workshops will be taking place on 12th January : \nWorkshop A: Digital Health – What are the real-world opportunities and potential barriers to adoption?\nWorkshop Leader: Andrew Dundon\, Founder\, PharMechceutics Ltd\n08.30 – 12.00  \nWorkshop B: Challenges and Drivers for Development of Long Acting Injectables\nWorkshop Leader: Joël Richard\, Chief Development Officer\, MedinCell\n13.00 – 17.00 \nEARLY-BIRD RATES: \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\nBOOK BY 30TH OCTOBER AND SAVE £200\nBOOK BY 30TH NOVEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.pre-filled-syringes.com/pjwl \nChairs for 2020: \n\nBjørg Kaae Hunter\, Department Manager\, RA CMC & Device; RA NextGen Drug-Device\,\nNovo Nordisk\nAlphons Fakler\, Head Medical Device Risk Management\, Novartis\n\nFeatured speakers:  \n\nBrian Holly\, Head of Human Factors\, Devices Centre of Excellence\, Pfizer \nDaniel Latham\, Head Device Development & LCM\, Novartis \nRene Holm\, Head and Scientifi c Director\, Drug Product Development\, Liquids and Parenterals\, Janssen\nStefano Martini\, Responsible for Special Programs\, Medical Devices Development\, Sanofi \nSarah Tang\, Regulatory Affairs Manager\, Devices Division\, MHRA \nAbha Raveau violette\, Device Manager\, AstraZeneca \nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck \nJulia Frese\, Director\, TÜV SÜD\nClemens Günther\, Director\, Senior Expert Nonclinical Safety\, Bayer \nJonathan Sutch\, Technical Specialist\, BSI\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nFollow us:  @SMiPharm #PFSSMi
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210120
DTEND;VALUE=DATE:20210122
DTSTAMP:20260515T052433
CREATED:20201117T084847Z
LAST-MODIFIED:20201117T084847Z
UID:27957-1611100800-1611273599@www.pharmajournalist.com
SUMMARY:Onco Cell Therapy Global
DESCRIPTION:Following the success of our first digital event in July with the likes of Carl June leading the keynote\, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations\, townhall meetings\, roundtable sessions and coffee break style networking. \n \nThe Global Onco Cell Therapy Summit is an online event\, 20th – 21st January 2021\, that provides a platform for information sharing to enable the discovery\, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma\, biotechs and academia. The summit will address the research\, regulatory\, logistical and technical challenges that are holding back the field. \nDelve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through: \n\nMeeting efficacies and safety targets as well as the scale of demands.\nDiscovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.\nOvercoming the challenging in scale up and automation of manufacturing\nRound table discussions on vectors and the promise of non-viral approaches.\nReimbursement strategies and their link to the latest developments in safety trials and regulatory standards\n\nWhilst bringing together the key decision makers for oncological cell therapies\, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments. \nNew for 2020 | Pre-event sessions: \n25th Nov | Manufacturing roundtable | FREE to attend \n15th Dec | ASH Review | FREE to attend \n19th Jan | NK Day | Registrants only \nVisit the website www.oncocelltherapyglobal.com for more details and to view the full agenda. (link to https://go.kisacoresearch.com/l/678123/2020-11-16/4r1xv). Don’t forget as a reader of Pharma Journalist\, quote PJ10 for a 10% discount.
URL:https://www.pharmajournalist.com/event/onco-cell-therapy-global/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T052433
CREATED:20201027T084532Z
LAST-MODIFIED:20201027T084532Z
UID:27681-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:TGFβ for Immuno-Oncology Drug Development Summit
DESCRIPTION:The world of TGFβ is at a tipping point within industry\, for an explosion of data to come.  \nExploring the wide array of approaches being utilized in pharma\, biotech\, and academia\, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta’s role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target.  \n \nDon’t miss out on your chance to deepen your understanding of cell signaling mechanisms\, change your view of the tumor microenvironment\, and prepare your candidates for the clinic to ensure patient safety.   \nJoin your peers this year to: \n\nHear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181\, their phase 1 candidate  \nDiscover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI\, and Clinical Development from Yan Lan at EMD Serono \n\n\nExplore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089 \nGet involved in Takeda\, Scholar Rock\, Oncotelic\, and Sanofi’s debate the best TGF-beta isoform to target\, combination vs monotherapy approaches\, and the winning therapeutic approach  \nContrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics  \n\n To know more about TGFβ for Immuno-Oncology Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/tgf%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T052433
CREATED:20201204T104141Z
LAST-MODIFIED:20201204T104141Z
UID:28158-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:4th Antigen Specific Immune Tolerance Summit (ASIT)
DESCRIPTION:The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n \nThis is the industry’s definitive antigen specific drug development forum. \nAcross 3 packed days\, thought leaders from Novartis\, ImCyse\, Harvard Medical School\, Toleranzia\, Toralgen will reveal insight\, data\, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders. \nTo know more about 4th Antigen Specific Immune Tolerance Summit (ASIT) please click here.
URL:https://www.pharmajournalist.com/event/4th-antigen-specific-immune-tolerance-summit-asit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T052433
CREATED:20201022T101624Z
LAST-MODIFIED:20201022T104507Z
UID:27586-1612828800-1613087999@www.pharmajournalist.com
SUMMARY:Gene Therapy Medical Affairs
DESCRIPTION:The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. \nIndustry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy\, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies. \n \nJoin this definitive\, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nThis virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement\, discussion\, and Q&A’s in order for you to get the best value from this meeting. \nTo know more about Gene Therapy Medical Affairs please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-medical-affairs/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T052433
CREATED:20201001T101330Z
LAST-MODIFIED:20201019T092845Z
UID:27319-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:RNA Therapeutics 2021
DESCRIPTION:Innovations in technologies and applications of RNA-based medicine \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. Furthermore\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, have triggered a major expansion of the RNA-therapeutics field. \nThe 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies\, oligonucleotide delivery\, therapeutic applications and future trends and innovations. \n \nJoin us in February 2021\, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry\, upcoming regulatory updates and industry implications. \nBENEFITS OF ATTENDING:  \n\nExplore in industry insights into how mRNA is being used to combat COVID-19\nEngage in case studies exploring the growing therapeutic potential of RNA for rare diseases\nDelve into future trends in AI application for optimal RNA therapeutics\nHear regulatory outlooks of the RNA landscape\, clinical trials and looking ahead\n\nView the full agenda and speaker line-up online: www.therapeutics-rna.com/pjwl \nFocus day on RNA Interference – 12TH February 2021\n\nAs the industry of RNA therapeutics advances this year’s focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome\, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery\, and targeted delivery of nucleic acid therapeutics. Furthermore\, this year’s focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry. \nEARLY-BIRD RATES:  \n\nBOOK BY 30TH OCTOBER AND SAVE £400\nBOOK BY 30TH NOVEMBER AND SAVE £200\nBOOK BY 11TH DECEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.therapeutics-rna.com/pjwl \nChairs for 2021: \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFocus Day Chair for 2021: Shalini Andersson\, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery\, AstraZeneca \nFeatured speakers:  \n\nDong Yu\, Fellow\, Senior Director\, and Head\, GSK Vaccines\nMaria Luisa Pineda\, CEO and Co-Founder\, Envisagenics\nKirsty Wydenbach\, Deputy Unit Manager/Senior Medical Assessor\, MHRA\nDong Ki Lee\, CEO\, OliX\nJennifer Pluim\, Vice President Medical Affairs\, ProQR\nArpan Desai\, Team Leader\, Advanced Drug Delivery\, Pharmaceutical Sciences\, AstraZeneca\nRuchi Shah\, Senior Research Engineer\, New Therapeutics Modalities\, Eli Lilly and Company\nMichael Mulqueen\, Vice President Business Development\, eTheRNA immunotherapies\nTroels Koch\, Founder & CEO\, Aqiventa\n\nWho should attend: \n\nResearch & Development Directors/Managers/Scientists\nHeads of Clinical Development\nHeads of Pre-Clinical Development\nHead of RNA Biology\nHead of RNA Formulation and Drug Delivery\nHead of Pre-clinical R&D\nHead of New Modalities\nHead of Discovery\nSenior Scientists\nChief Scientific Officers\nChief Medical Officers\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nFollow us:  @SMiPharm #SMirna
URL:https://www.pharmajournalist.com/event/rna-therapeutics-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T052433
CREATED:20201012T114728Z
LAST-MODIFIED:20201012T114728Z
UID:27476-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:Sponsored by: Celvivo \nChaired by: Stefan Przyborski\, Professor of Cell Technology\, Durham University \nDeveloping Complex Physiologically Relevant Cell Models in Vitro \n3D Cell Culture is gaining momentum in the pharmaceutical industry\, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery\, predictivity and validation\, safety\, and toxicity. \n \nSMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development\, toxicity testing\, and safety assurance. In addition\, the conference will look into the newest breakthroughs in Organ Chip technology\, 3D Multicellular scaffolding\, Microphysiological Systems\, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application. \nEvent Hashtag: #SMi3DCellCulture \nHIGHLIGHTS FOR 2021 \n\nDiscover the cutting-edge technology that is changing the face of pharmaceutical drug development\nExplore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives\nInsight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro\nDiscuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery\nAssess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops\n\nFEATURED SPEAKERS INCLUDE: \n\nSuzanne Fitzpatrick\, Senior Advisor for Toxicology\, US Food and Drug Administration\nPelin Candarlioglu\, Investigator – Bioengineer/Cell Biologist\, GSK\nRobert Vries\, CEO\, Hubrecht organoid Technology\nSakshi Garg\, Lab Head\, Discovery & Development Technologies\, Merck Group\nRhiannon David\, Scientific Lead Microphysiological Systems\, AstraZeneca\nStephen J. fey\, Founder and Chief Research Officer\, CelVivo\nAlejandro Amador\, Director\, Cellular Assays and Technologies\, Incyte\nFreddy Van Goethem\, Scientific Director – Fellow\, Predictive\, Investigative\, and Translational Toxicology\, Johnson & Johnson; Janssen Pharmaceutical\nJulian Bahr\, Postdoctoral Fellow\, Oncology\, AstraZeneca\nPedro Pinto\, Laboratory Manager\, Urology\, university of Greifswald – Medical Centre\n\nView the full agenda: www.3D-cellculture.com/PJwl \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist Academia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering Solution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210213
DTSTAMP:20260515T052433
CREATED:20201109T113504Z
LAST-MODIFIED:20201109T113504Z
UID:27864-1612915200-1613174399@www.pharmajournalist.com
SUMMARY:5th Annual Liquid Biopsies for Precision Oncology Summit
DESCRIPTION:Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit! \nWith two exciting LBx approvals in 2020 and investment pouring into the industry\, these assays are primed to transform the cancer-care space. To realize these untapped opportunities\, it is essential significant sensitivity\, selectivity and analytical roadblocks are addressed to prove utility in the clinic. \n \nThe 5th Annual Liquid Biopsy for Precision Oncology Summit is a crucial date in the industry calendar\, bringing together the entire value chain of oncology drug development to hear and collaborate around the latest advancements innovating cancer detection\, diagnosis and monitoring. \nThis completely online meeting will allow you to discover how latest technologies are being applied to accurately detect and analyze circulating biomarkers earlier\, effectively monitor treatment response and selectively stratify patient populations to enable delivery of targeted therapies in a time-efficient manner. \nFrom biomarker validation through to reimbursement and regulatory\, join your drug development peers striving to translate the clinical applications of liquid biopsies into a worldwide patient reality. \nTo know more about 5th Annual Liquid Biopsies for Precision Oncology Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-annual-liquid-biopsies-for-precision-oncology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210216
DTEND;VALUE=DATE:20210219
DTSTAMP:20260515T052433
CREATED:20201020T125856Z
LAST-MODIFIED:20201020T130956Z
UID:27553-1613433600-1613692799@www.pharmajournalist.com
SUMMARY:CAR-TCR Summit Europe 2021
DESCRIPTION:Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe\, Effective & Affordable Advanced Therapies \n \nThe CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs\, breach the solid tumor microenvironment\, and deliver affordable CAR and TCR technologies to patients in need. \nProviding you with the most comprehensive program this side of the Atlantic\, this summit brings you exclusive insights from the innovators breaking the glass ceiling in T cell engineering\, manufacturing\, safety management and patient accessibility. \nTo know more about CAR-TCR Summit Europe 2021 please click here.
URL:https://www.pharmajournalist.com/event/car-tcr-summit-europe-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T052433
CREATED:20201021T150805Z
LAST-MODIFIED:20201021T150805Z
UID:27572-1613952000-1614297599@www.pharmajournalist.com
SUMMARY:Gene Therapy for Rare Disorders USA
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith investment at an all-time high\, and several indications in late-stage trials gearing up for approval\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies drug developers are employing to improve efficacy\, safety and commercial viability. \n \nIncorporating insights from 90+ industry-leading speakers\, this digital conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 500+ of your colleagues online to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-rare-disorders-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210225
DTSTAMP:20260515T052433
CREATED:20201111T111102Z
LAST-MODIFIED:20201111T111102Z
UID:27878-1613952000-1614211199@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs
DESCRIPTION:Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need: Say Goodbye to the Worry and Uncertainty of Setting Up and Managing an Expanded Access Program. \n \nBy bringing together the world’s leading thinkers in Expanded Access Programs\, this exclusive platform will clarify the complex issues through end-to-end Expanded Access Program Operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivalled opportunity to solve your challenges across the entire program timeline. \nOver the course of 3 interactive days\, 20 expert speakers will share their insights on program set-up\, US and EU regulatory pathways\, product supply\, data collection\, using technology to streamline processes and patient communication\, closing out programs and moving to commercialization. So\, next February\, join your peers from across the value chain to develop your own toolkit of solutions from the only case study led\, operationally–focused access programs event. \nTo know more about Operationalize: Expanded Access Programs please click here.
URL:https://www.pharmajournalist.com/event/operationalize-expanded-access-programs/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:nfo@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T052433
CREATED:20210114T085910Z
LAST-MODIFIED:20210122T141443Z
UID:28470-1613952000-1614124799@www.pharmajournalist.com
SUMMARY:Animal Health Innovation Europe
DESCRIPTION:The 6th Annual Animal Health Innovation Europe taking place on the 22-23rd February 2021 will showcase the most exciting innovations in animal health and nutrition\, connecting those businesses with financial investors and strategic corporate partners\, making it the sector’s premier investment forum in Europe. \n \nJoin us to hear investment pitches\, network with C-Suite Executives and learn from CEO-level panel discussions that address the trends and market dynamics of the animal health industry\, across all species. This year’s virtual format gives us a unique opportunity with our programming to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners\, veterinarians\, and farmers today. We have advanced our networking capabilities to help you recreate the unexpected business interactions that are so valuable at our face-to-face events\, through virtual roundtable discussions\, workshop groups and interactive content delivery. \nFeaturing speakers from industry leaders such as Elanco\, Zoetis\, Phibro\, and many more\, 2021 content will cover expanded insights on: sustainability and efficiency in the protein supply chain\, the accelerated use of digital solutions in the pet sector\, how the animal health industry will continue to generate value through the Covid-19 pandemic\, and new approaches to stimulate technology adoption and enhance the productivity of European farmers. \nJoin us for the innovation showcase\, a feature of the event that is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. Split between companion and production animal sectors\, 20 start-ups\, hand-picked by the Selection Committee (who all have an extensive breadth of experience and knowledge across animal health and nutrition industries)\, introduce themselves and their innovations and achievements on the main stage. \nBook now to join us in shaping the future of animal health.
URL:https://www.pharmajournalist.com/event/animal-health-innovation-europe/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T052433
CREATED:20200525T084418Z
LAST-MODIFIED:20201123T135747Z
UID:25675-1614038400-1614124799@www.pharmajournalist.com
SUMMARY:Purify'20
DESCRIPTION:PURIFY – Chromatography Purification Conclave \nPURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \n \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. (For more details please visit: https://www.linkedin.com/showcase/purifyconclave/) PURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nThe knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nLooking forward to seeing you at PURIFY’20!\nV: ITC Kohenur\, Hyderabad\nD: 23 February\, 2021\nTo book your seats please call Rashi: +91-91366 00573
URL:https://www.pharmajournalist.com/event/purify20/
LOCATION:ITC Kohenur\, Hyderabad\, India
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T052433
CREATED:20201109T080924Z
LAST-MODIFIED:20201109T081324Z
UID:27836-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:RAS – Targeted Drug Discovery – Digital Summit
DESCRIPTION:Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However\, their specificity to only target G12C mutations\, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike. \n \nThe Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular\, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C. \nAs part of our industry leading and dedicated RAS conference series\, this exciting next iteration is shining the spotlight on: \n§     Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms \n§     Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies \n§     Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer \nJoin senior experts from leading biotech\, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic. \nTo know more about RAS – Targeted Drug Discovery please click here.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-digital-summit/
LOCATION:Digital Event\, GMT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T052433
CREATED:20201111T111739Z
LAST-MODIFIED:20201111T111739Z
UID:27882-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:9th Neurodegenerative Drug Development Summit
DESCRIPTION:The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. \n \nBuilding on the success of last year’s meeting\, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets\, novel modalities and innovative trial design. Across 3 action-packed\, case-study driven days and 2 parallel tracks of learning\, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit. \nWhether you are working in a team dedicated to Parkinson’s\, Alzheimer’s\, ALS\, Frontotemporal Dementia or a rare neurodegenerative disorder\, join this intimate\, industry-led forum to not only to learn from those spearheading this space\, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. \nTo know more about 9th Neurodegenerative Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-neurodegenerative-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T052433
CREATED:20201022T103840Z
LAST-MODIFIED:20201022T104916Z
UID:27595-1615248000-1615507199@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders 2021
DESCRIPTION:2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program\, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field\, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market. \n \nThe 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021\, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia\, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality. \nTo know more about Gene Therapy for Blood Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210313
DTSTAMP:20260515T052433
CREATED:20210226T095658Z
LAST-MODIFIED:20210226T100244Z
UID:29127-1615420800-1615593599@www.pharmajournalist.com
SUMMARY:2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference
DESCRIPTION:The Diagnostics sector has emerged as a prominent game changer in healthcare\, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions\, it needs to be quicker\, précised\, and accurate. \nPoint-of-care testing (POCT) is a growing testing. Today\, you may see POCT in a hospital with handheld gadgets or small testers in emergency department\, extensive care setting\, popular clinical wards\, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient’s point of care. \n \nIn the era of improved diagnostics\, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional\, Industrial specialists\, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool. \nEvent Website: https://bit.ly/3gNnkOq \nRegistration link: https://bit.ly/3oRX7kH
URL:https://www.pharmajournalist.com/event/2nd-annual-marketsandmarkets-infectious-disease-diagnostics-and-point-of-care-testing-virtual-conference/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T052433
CREATED:20210226T105316Z
LAST-MODIFIED:20210226T111537Z
UID:29175-1615420800-1615507199@www.pharmajournalist.com
SUMMARY:MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
DESCRIPTION:High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event \nThe end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy\, Gene Therapy\, Monoclonal Antibodies\, Vaccines\, biosimilars and biobetters\, plasma therapy as well as others. \nA host of attractive\, high growth opportunities such as single use systems\, Lab Scale and CGMP manufacturing and R&D\, Crispr and other Gene editing tools and technologies\, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs\, CMOs\, Bioprocess solutions manufacturers\, Biobanks\, automation technology providers etc can benefit from this unprecedented growth over the next 5 years. \nThis Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem\, as seen through the lens of eminent CXOs in this space \nEvent Website: https://bit.ly/3qJYdQF  \nRegistration link: https://bit.ly/2Mcpg8i 
URL:https://www.pharmajournalist.com/event/marketsandmarkets-biopharma-manufacturing-crystal-ball-event-time-zone-9am-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210318
DTSTAMP:20260515T052433
CREATED:20201214T152316Z
LAST-MODIFIED:20201214T152538Z
UID:28302-1615766400-1616025599@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress 2021
DESCRIPTION:Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins\, therefore making it an obvious target. With Risdiplam being approved by the FDA in August\, and several major collaborations also being penned throughout 2020\, including a $190 million deal between Arrakis and Roche\, it seems like a good time to target these protein precursors. \n \nThe Targeting RNA Congress will return for 2021\, March 15-17\, and will take a look at the latest techniques to analyse and predict protein structure\, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent\, rather than treat\, disease. \nKey Outcomes from the summit include: \n\nLearn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure\, including NMR\, Cryo-EM\, and in silico modelling with Silvi Rouskin\, (MIT)\, Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).\nUnderstand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).\nGet translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)\nHear what new techniques can help to drug these tricky targets\, including RNAi\, RNA degraders and RIBOTACs with Gene Yeo (UCSD)\, Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).\n\nTo know more about Targeting RNA Congress please click here.
URL:https://www.pharmajournalist.com/event/targeting-rna-congress-2021/
LOCATION:Virtual Summit EST Timezone
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210317
DTSTAMP:20260515T052433
CREATED:20201223T083652Z
LAST-MODIFIED:20201223T083652Z
UID:28371-1615766400-1615939199@www.pharmajournalist.com
SUMMARY:SMi’s 2nd Annual AI in Drug Discovery
DESCRIPTION:Chaired by: Darren Green\, Director of Molecular Design & Senior Fellow\, GSK \nSponsored by: OpenEye Scientific Software \nExploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines \nSMi is proud to present its 2nd Annual AI in Drug Discovery Conference\, taking place on the 15-16 March 2021. \nWith the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3\,900 million by 2027\, the conference agenda will encompass key drivers leading the way into a shorter\, cheaper\, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech\, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’. \n \nFurthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases\, and will highlight key case studies across these themes\, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail \nEvent Hashtag: #SMiAIDrugDis \nHIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscover the latest innovations in AI-based drug discovery platforms\nEngage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines\nUnderstand how AI can be effectively implemented to enhance productivity\nDelve into best practices in data quality\, curation\, and validation\nExplore how AI is being used to unlock therapies that have evaded traditional drug discovery\n\nKEY SPEAKERS INCLUDE \n\nNoor Shaker\, CEO\, Glamorous AI\nMaria Luisa Pineda\, Co-Founder & CEO\, Envisagenics\nEd Addison\, Co-founder\, Chairman\, and CEO\, Cloud Pharmaceuticals\nLiling Warren\, Director\, Head of Translational Medicine Statistics\, Teva Pharmaceuticals\nLili Peng\, Associate Director Scientific Ecosystem Analytics Lead\, Biogen\nMark De Pristo\, CEO\, BigHat Biosciences\nPhilipe Moingeon\, Head of Immuno-inflammation\, Servier\nHugo Ceulemans\, Scientific Director\, Discovery Data Sciences\, Janssen\nPeter Henstock\, Machine Learning & AI Lead\, Pfizer\nNaheed Kurji\, CEO\, Cyclica\n\nWHO SHOULD ATTEND \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-2nd-annual-ai-in-drug-discovery/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210322
DTEND;VALUE=DATE:20210324
DTSTAMP:20260515T052433
CREATED:20201028T124553Z
LAST-MODIFIED:20201028T124553Z
UID:27686-1616371200-1616543999@www.pharmajournalist.com
SUMMARY:Parallel Trade 2021 – Virtual conference: online access only
DESCRIPTION:Exploring the challenges\, practices and drivers in the aftermath of the transition for Parallel Trade \nSMi present’s its 15th annual Parallel Trade virtual conference\, taking place virtually on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \n\nThe 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nRegister online for only £999: www.parallel-trade.com/pjwl    \nThe benefits of attending: \nLearn new perspectives and case studies through presentation\, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans. \nPlus\, one post-conference interactive workshop \nWorkshop: The law of parallel trade: past\, present and future\nWorkshop Leaders:\nChristopher Stothers\, Partner\, Bruckhaus Freshfields Deringer\nSharon Malhi\, Senior Associate\, Antitrust\, Competition and Trade\, Bruckhaus Freshfields Deringer \n Who should attend: \nVice President/ Heads of/General Managers: \n\nInternational Trade and Relations\nSupply Chain Development – Brexit\nBrexit Implementation\nMarket Access\nSupply Chain Manager\nParallel trade reporting\nRegulatory Affairs\nIP\nPurchasing\nPolicy Patent Operations\nEuropean Affairs\nSupply and Demand\nAttorney\nDistribution\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMi #SMiParallel
URL:https://www.pharmajournalist.com/event/parallel-trade-2021-virtual-conference-online-access-only/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T052433
CREATED:20210119T095042Z
LAST-MODIFIED:20210119T095042Z
UID:28574-1616457600-1616716799@www.pharmajournalist.com
SUMMARY:FcRn-Targeted Therapies for Autoimmune Disorders Summit
DESCRIPTION:The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis\, half-life extension\, and recycling of human serum albumin and IgG\, however in the case of more than 100+ rare and autoimmune disorders\, this can not only be detrimental\, but lethal to the health of the individual. Following the high profile J&J-Momenta deal\, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020\, other large players are poised to bring their candidates through the clinic in rapid succession. \n \nThe digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first\, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. \nThe 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. \nJoin 100+ experts online from companies such as CSL Behring\, Eli Lilly\, Roche\, Momenta\, Alexion\, Argenx and more to discuss FcRn MOA\, preclinical model selection and translation\, high throughput assays for ligand screening\, IgG engineering\, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.
URL:https://www.pharmajournalist.com/event/fcrn-targeted-therapies-for-autoimmune-disorders-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260515T052433
CREATED:20210226T101236Z
LAST-MODIFIED:20210226T101236Z
UID:29150-1616457600-1616630399@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
DESCRIPTION:One of the major challenges faced by the players in this market\, especially CMOs that offer HPAPI manufacturing services\, is the continual evolution of industry standards\, technologies\, and regulations. \nOwing to their target release characteristics\, HPAPIs find major applications in target therapies for cancer. Globally\, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases\, glaucoma\, and specifically cancer have a significant impact on the health status of people worldwide\, with comparatively higher growth rates in developing countries. \nThe 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards\, technologies\, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations\, live case studies and breakthrough panel discussions. \nEvent Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register  
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference-cet-time-zone/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T052434
CREATED:20201119T113716Z
LAST-MODIFIED:20201119T113716Z
UID:27982-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit
DESCRIPTION:Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment \nThe renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs\, not only as single agents\, but also in combination with other immunomodulatory drugs. \n \nTherapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor\, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state\, acting as a complementary strategy to a suite of cancer immunotherapies approaches. \nThe virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients. \nJoin us and leading experts from Roche\, CytomX\, Philogen\, Bristol-Myers Squibb\, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose\, determining the mechanisms of action and hear the latest data coming out of the clinic. \nTo know more about Cytokine-Based Cancer Immunotherapies Summit please click here.
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T052434
CREATED:20210114T091620Z
LAST-MODIFIED:20210122T141247Z
UID:28478-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Animal Microbiome Congress
DESCRIPTION:The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat\, aquaculture\, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events\, we have built an international animal microbiome community of 600+ people from 30+ countries. \n \nThrough comprehensive industry-academic discussion panels\, engaging keynotes\, interactive roundtables\, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals\, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format\, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters\, Deep Dive Roundtable groups of 9 people working together to tackle industry issues\, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically. \nJoin us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture\, production\, and companion animals\, improving health outcomes for production and companion animals\, reducing the cost of animal ownership and making farming more sustainable\, and translating academic research into commercial products whilst steering through challenging regulatory hurdles. \nBook now to join us in unlocking the full functional potential of the Animal Microbiome.
URL:https://www.pharmajournalist.com/event/animal-microbiome/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR